Discovery of EU-129 for treatment of severe COVID-19 in patients with underlying diseases April 19, 2021
Promising results for triple A1/A2A/A2B adenosine receptor antagonist in cancer immunotherapy April 15, 2021
Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor April 14, 2021
RSS